Medical Condition

pancreatic adenocarcinoma

Total Trials

14

Recruiting Now

14

Trial Phases

Phase 2, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for pancreatic adenocarcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pancreatic adenocarcinoma Clinical Trials

How many clinical trials are currently recruiting for pancreatic adenocarcinoma?

ClinicalMetric currently tracks 14 actively recruiting clinical trials for pancreatic adenocarcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for pancreatic adenocarcinoma?

pancreatic adenocarcinoma research spans Phase 1 (6 trials), Phase 2 (7 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a pancreatic adenocarcinoma clinical trial?

Eligibility criteria for pancreatic adenocarcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

M.D. Anderson Cancer Center 1 trial

Liu Huang 1 trial

Fudan University 1 trial

Baylor Research Institute 1 trial

UNC Lineberger Comprehensive Cancer Center 1 trial

Recruiting Clinical Trials

NCT01365169

Recruiting

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

M.D. Anderson Cancer Center

View Trial →

NCT06199895 Phase 2

Recruiting

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Baylor Research Institute

View Trial →

NCT06483555 Phase 1, Phase 2

Recruiting

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

UNC Lineberger Comprehensive C...

View Trial →

NCT05208762 Phase 1

Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Enrollment

714 pts

Location

United States, Belgi...

Sponsor

Seagen, a wholly owned subsidi...

View Trial →

NCT06387342 Phase 2

Recruiting

Namodenoson Treatment of Advanced Pancreatic Cancer

NCT03384238 Phase 1, Phase 2

Recruiting

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Enrollment

2,020 pts

Location

United States, Franc...

Sponsor

Guardant Health, Inc.

View Trial →

NCT05245500 Phase 1

Recruiting

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

University of Louisville

View Trial →

NCT07493421

Recruiting

To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.

Unidade Local de Saúde São Joã...

View Trial →

NCT06399757 Phase 1, Phase 2

Recruiting

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

Apollo Therapeutics Ltd

View Trial →

Related Conditions

cholangiocarcinoma (2) esophageal carcinoma (2) squamous cell carcinoma of the head and neck (2) non small cell lung cancer (2) gastric adenocarcinoma (2) malignant head and neck neoplasm (1) malignant neoplasm (1) metastatic malignant neoplasm in the neck (1) metastatic malignant neoplasm in the uterine cervix (1) pancreatic neuroendocrine carcinoma (1) recurrent colorectal carcinoma (1) stage i colorectal cancer ajcc v6 and v7 (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology